Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.
Benjamin Levy, MD, thoracic medical oncologist, clinical director, Medical Oncology, the Johns Hopkins Sidney Kimmel Cancer Center, discusses the efficacy findings of the combination of datopotamab deruxtecan (DS-1062a) and pembrolizumab (Keytruda), with or without chemotherapy, in non–small cell lung cancer (NSCLC).
The dose escalation, open label, phase 1b TROPION-Lung02 trial (NCT04526691) is examining the antibody-drug conjugate (ADC) datopotamab deruxtecan in combination with pembrolizumab, with or without chemotherapy, in patients with untreated or previously treated metastatic NSCLC.
Within TROPION-Lung02 trial, 2 cohorts of patients received the doublet of datopotamab deruxtecan and pembrolizumab, and 4 cohorts of patients were administered the ADC with pembrolizumab and carboplatin or cisplatin, Levy says. In the cohorts of treatment-naïve patients, the doublet and the triplet elicited overall response rates (ORRs) of 62% and 50%, respectively, Levy adds. The disease-control rate was 100% for the doublet and 90% for the triplet in the first-line setting, Levy continues.
In the overall population, irrespective of treatment setting, the ORRs for the doublet and triplet were 37% and 41%, respectively.
Given the durability of the responses in the first-line setting, further exploration of the datopotamab deruxtecan combinations in that setting will be vital, Levy adds. Additional studies could lead to more promising data in the future, Levy concludes.